netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 4: Central nervous system - Full Chapter
Chapter Links...
 Details...
04.03.04  Expand sub section  Other antidepressant drugs
Mirtazapine
View adult BNF View SPC online View childrens BNF
Formulary
Green

Can be used as monotherapy or in combination with a SSRI (e.g. sertraline or citalopram) or SNRI (e.g. duloxetine or venlafaxine), for the treatment of depression as per prescribing algorithm and full prescribing guidelines.

Combined treatments are associated with a higher side effect burden and may require additional monitoring.

APCO November 2020.

 
   
Flupentixol (Fluanxol®)
(Antidepressant)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Continuation

Suitable for prescribing in primary care following specialist recommendation.

 
   
Venlafaxine
View adult BNF View SPC online View childrens BNF
Formulary

Green Traffic Light As third line treatment for depression, as per prescribing algorithm and full prescribing guidelines

Monitor blood pressure. Prominent discontinuation symptoms. Avoid if at risk of arrhythmia or in uncontrolled hypertension. Greater risk in overdose than most SSRIs

APCO November 2020.

Black Traffic Light  Not licensed for controlling hot flushes. Not recommended for prescribing. 

APCO November 2005.

 
   
Venlafaxine XL (Vensir® XL)
(Modified-release capsules)
View adult BNF View SPC online View childrens BNF
Formulary

Green Traffic Light  For Generalised Anxiety Disorder: Alternative first line options when an SSRI is contraindicated. See Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults.

APCO September 2017

Green Traffic Light  As third line treatment for depression, as per prescribing algorithm and full prescribing guidelines

APCO November 2020.

NB. Vensir® XL capsules is the most cost-effective prolonged-release formulation, see Prescribing Points March 2017.

Black Traffic Light  Not licensed for controlling hot flushes. Not recommended for prescribing. 

APCO November 2005.

 
   
Duloxetine
View adult BNF View SPC online View childrens BNF
Formulary
Green

 

 
   
Reboxetine
View adult BNF View SPC online View childrens BNF
Formulary
Amber Continuation

Not included in current guideline for routine treatment as it has been shown to have a lower efficacy and tolerability profile when compared with other antidepressants.  Prescribing may continue in existing patients only where efficacy has been clearly demonstrated, as per prescribing algorithm and full prescribing guidelines.

APCO November 2020.

 
   
Vortioxetine (Brintellix®)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Continuation

Suitable for prescribing in primary care for treatment of depression following specialist recommendation, as per prescribing algorithm and full prescribing guidelines

Also see Oxford Health Medicines Information Bulletin: Vortioxetine for depression.

Option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode as per NICE TA367.

APCO November 2020.

 
Link  NICE TA367: Vortioxetine for treating major depressive episodes
   
Agomelatine (Valdoxan®)
View adult BNF View SPC online View childrens BNF
Formulary

Red Traffic Light Specialist prescribing only as the fourth line treatment for Generalised Anxiety Disorder. See Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults.

APCO September 2017

Amber Traffic Light Suitable for continuation in primary care for the treatment of depression following specialist initiation and stabilisation, as per prescribing algorithm and full prescribing guidelines. Patients should remain under the care of an Oxford Health specialist until all scheduled LFT monitoring is complete and results are normal (minimum of 24 weeks, or for 24 weeks from the date of a dose increase). Only at this point, and only if the patient is well, should a patient be discharged back to GP care.

APCO November 2020.

 
   
 ....
 Non Formulary Items
Tryptophan

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary